Brief: Marker Therapeutics Updates On Clinical Readiness For MT-401 Off-The-Shelf Program
07/08/2023 15:41
Aug 7 (Reuters) - Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS REPORTS NON-CLINICAL PROOF-OF-CONCEPT
DATA
AND UPDATE ON CLINICAL READINESS FOR THE MT-401 OFF-THE-SHELF
PROGRAM
* MARKER THERAPEUTICS INC - ANTICIPATES THAT FIRST PATIENT
WILL BE
TREATED WITH MT-401 OTS DURING FIRST HALF OF 2024
Source text for Eikon: ID:nGNX8dDDMQ
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79